论文部分内容阅读
Despite decades of research and an emerging understanding of the molecular biology of disease, the prognosis for patients diagnosed with hepatocellular carcinoma (HCC) remains poor. Epidemiologic surveys continue to show a rising incidence of disease and therapeutic options remain largely ineffective.